EX-10.11.2





 Exhibit 10.11.2 

SUPPLEMENTAL AGREEMENT 

THIS SUPPLEMENT AGREEMENT dated as of the 14th day of August, 2018 (the “Supplemental Agreement”) is made between SBI Biotech
Co., Ltd., a Japanese corporation having its principal office at 1-6-1 Roppongi, Minato-ku, Tokyo, Japan
(“SBIBT”) and Viela Bio, Inc., having its principal place of business at One MedImmune Way, Gaithersburg, Maryland 20878 (“Viela Bio”). 

RECITALS 
 WHEREAS, SBIBT
and Medimmune, LLC. (“MedImmune”) entered into the LICENSE AGREEMENT dated as of the 9th day of September, 2008 (the “License Agreement”); 

WHEREAS, MedImmune has assigned the License Agreement to Viela Bio as of the 6th day of March, 2018, in connection with the spinoff of Viela
Bio from MedImmune; and 
 WHEREAS, SBIBT and Viela Bio wish to amend the License Agreement and entered into this Supplemental Agreement.

 NOW THEREFORE, in consideration of the premises and of the covenants herein contained, the Parties hereto mutually agree as follows: 

ARTICLE 1 
 DEFINITIONS

 The terms defined in the License Agreement which are not otherwise defined in this Supplemental Agreement shall have the same meaning
as defined in the License Agreement. 
 ARTICLE 2 

ASSIGNMENT 
 2.1 SBIBT and
Viela Bio confirm that MedImmune has assigned the License Agreement to Viela Bio as of the 6th day of March, 2018 (the “Assignment Date”) in accordance with Section 12.2(a) of the License Agreement, and all rights and
obligations under the License Agreement as of the Assignment Date shall be succeeded to by Viela Bio. 
 2.2 As a consequence of the
assignment of the License Agreement set forth in Section 2.1 of this Supplemental Agreement, unless the context requires otherwise, the term “MedImmune” in the License Agreement shall be replaced with the term “Viela Bio” as
of the Assignment Date. 
 ARTICLE 3 

COMMITMENT 
 3.1 Viela Bio
shall start the first human doses in a Phase II Clinical Trial before the [***] and pay the corresponding milestone set forth in Section 4.1(iii) of this Supplemental Agreement to SBIBT in accordance with the License Agreement and this
Supplemental Agreement. 

  
 [*] = CERTAIN CONFIDENTIAL
INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 













 3.2 Where Viela Bio foresees that it is not able to start the first human doses in a Phase
II Clinical Trial before the [***], Viela Bio shall promptly notify SBIBT in writing specifying the reasons for the delay. If the reasons for the delay are not due to Viela Bio’s lack of diligence in SBIBT’s reasonable judgment, SBIBT will
grant an extension of the start date for the first human doses in a Phase II Clinical Trial up until the [***] by entering into a written agreement with Viela Bio, provided that SBIBT shall not unreasonably refuse to agree with an extension. 

ARTICLE 4 
 MILESTONE
PAYMENT 
 4.1 SBIBT and Viela Bio agree that if Viela Bio starts the first human doses in a Phase II Clinical Trial before the [***],
or the extended start date agreed by the parties pursuant to Section 3.2 of this Supplemental Agreement, if applicable, the amount of milestone payments to be paid by Viela Bio to SBIBT as listed in Section 5.2(a) of the License Agreement
shall be automatically amended as indicated below: 
  

			
	 (i) [***]
	  	$[***]
	 (ii)  [***]
	  	$[***]
	 (iii)  [***]
	  	$[***]
	 (iv) [***]
	  	$[***]
	 (v)   [***]
	  	$[***]
	 (vi) [***]
	  	$[***]
	 (vii) [***]
	  	$[***]
	 (viii)[***]
	  	$[***]
	 (ix) [***]
	  	$[***]
	 (x)   [***]
	  	$[***]

 4.2 If and when the change in the amount of the milestone payment under Section 4.1 of this Supplemental
Agreement applies, the aggregate amount of the milestones set forth in Section 5.2(b) of the License Agreement shall be automatically amended to [***] ($[***]). 

4.3 If the first doses in a Phase II Clinical Trial are not started before the [***], or the extended start date agreed by the parties
pursuant to Section 3.2 of this Supplemental Agreement. if applicable, Viela Bio shall pay the milestone payment in accordance with the original amount set forth in Section 5.2 of the License Agreement. 

4.4 To avoid doubt, except as otherwise expressly agreed under this Supplemental Agreement, the original terms under the License Agreement
regarding payment of the milestone shall be applied regardless of whether or not Viela Bio starts the first human doses in a Phase II Clinical Trial before the [***], or the extended start date agreed by the parties pursuant to Section 3.2 of
this Supplemental Agreement, if applicable. 
 4.5 SBIBT hereby acknowledges that the milestone payments set forth in Section 5.2(a)(i)
and (ii) of the License Agreement have been timely paid. 

  
 2 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 













 ARTICLE 5 

NOTICE 
 SBIBT and Viela
Bio agree that, effective as of the Assignment Date, the address of each Party under Section 12.3 of the License Agreement shall be changed to the following: 

If to SBIBT: 
 SBI Biotech Co.,
Ltd. 
 1-6-1 Roppongi,
Minato-ku, Tokyo, Japan 
 Attn: Representative Director & President with a copy to 

Licensing and Partnering Section, Research and 

Development Department 

Facsimile: +81-3-3583-2022 

If to Viela Bio: 
 Viela Bio,
Inc. 
 One MedImmune Way, Gaithersburg, Maryland 20878 

Attn: CEO with a copy to Business Development 

Email: bd@vielabio.com 

Fax: 240-772-9578 

ARTICLE 6 
 TERM 

This Supplemental Agreement shall be effective as of the date first set forth above and shall continue in effect until termination or expiration of the
License Agreement. 
 ARTICLE 7 

MISCELLANEOUS 
 7.1 SBIBT
and Viela Bio agree that the License Agreement shall remain in full force and effect in accordance with its terms and conditions, except the portions amended by this Supplemental Agreement. All references in the License Agreement shall, unless the
context requires otherwise, be read and construed as a reference to the License Agreement as amended by this Supplemental Agreement. 
 7.2
This Supplemental Agreement shall be governed by and construed in accordance with the laws of the State of New York, U.S.A., without regard to any choice of law principles that would dictate the application of the laws of another jurisdiction. Any
disputes arising between the Parties relating to, arising out of or in any way connected with this Supplemental Agreement or any term or condition hereof, or the performance by either Party of its obligations hereunder, shall he resolved in
accordance with Section 12.5 of the License Agreement. 
 7.3 This Supplemental Agreement may be executed in any number of
counterparts, each of which when executed and delivered shall constitute an original, but all the counterparts shall together constitute one and the same instrument. 

  
 3 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. 













 IN WITNESS WHEREOF, the Parties have caused this Supplemental Agreement to be executed by their respective
duly authorized representatives as of the date first set forth above. 
  

					
	VIELA BIO, INC.	 		 	SBI BIOTECH CO. LTD.
			
	By: /s/ Aaron Ren	 		 	By: [***]
	Name: Aaron Ren	 		 	Name: [***]
	Title: Head of BD and Ops	 		 	Title: Representative Director & President


  
 4 

[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II)
WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.